TREATMENT OF BEHÇET’S DISEASE AND CURRENT APPROACHES
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of Ankara
Access Rights
info:eu-repo/semantics/openAccess
Abstract
Objective: Behçet's Disease (BD) is a multisystemic inflammatory disease which courses with relapses and characterized by four major symptoms of oral aphthous ulcers, genital ulcers, skin lesions and ocular lesions; and five minor symptoms including joint involvement, gastrointestinal ulcers, epididymitis, vascular lesions and neurological involvement. Treatment in BD varies according to the clinical course of age at which the disease begins, gender, the organs involved and the clinical course of the disease; therefore, it should be performed according to the person and the symptoms. While empirical treatment of BD is still continuing; recently, effective protocols have been implemented due to the pathogenesis of the underlying disease that is better defined and many broad-spectrum therapeutic agents have been presented for the treatment. This review is presented to bring together the specific treatment procedures applied during the progression of the disease. Result and Discussion: Although there is no specific treatment strategy for BD, which is an inflammatory disease characterized by local and systemic involvements, treatment procedures range from local corticosteroids to monoclonal antibodies, determined by the type and severity of symptoms. Studies are still continuing on diseases affecting the vascular and gastrointestinal system in BD. Conventional immunosuppressive agents, including corticosteroids, colchicine and azathioprine, and cyclosporine are used in the treatment of BD. Recently, tumor necrosis factor (TNF) inhibitors have become available for a variety of rheumatic diseases, and published data indicate that TNF inhibitors represent a significant therapeutic advance for patients with severe and resistant disease as well as those with contraindications or intolerance to these therapies. © 2022 University of Ankara. All rights reserved.
Description
Keywords
Anti-Tnf-?; Behçet's Disease; Glucocorticoids; Major Organ Involvements; Mucocutaneous Ulceration, Adalimumab; Alemtuzumab; Anakinra; Apremilast; Azathioprine; Benzathine Penicillin; Canakinumab; Certolizumab Pegol; Colchicine; Corticosteroid; Cyclophosphamide; Cyclosporine; Daclizumab; Dapsone; Etanercept; Gevokizumab; Glucocorticoid; Golimumab; Immunologic Factor; Immunosuppressive Agent; Infliximab; Levamisole; Methotrexate; Monoclonal Antibody; Mycophenolate Mofetil; Pentoxifylline; Rebamipide; Recombinant Alpha Interferon; Rituximab; Salazosulfapyridine; Secukinumab; Tacrolimus; Tocilizumab; Tumor Necrosis Factor Inhibitor; Ustekinumab; Zinc Sulfate; Behcet Disease; Cardiovascular System; Disease Exacerbation; Disease Severity; Environmental Factor; Gastrointestinal Tract; Heredity; Human; Immunopathogenesis; Pathophysiology; Review; Rheumatic Disease; Symptom Assessment; Treatment Planning
Journal or Series
Ankara Universitesi Eczacilik Fakultesi Dergisi
WoS Q Value
Scopus Q Value
N/A
Volume
46
Issue
2
